Premium
Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen–Friedenreich Antigen and a Fluorine‐Substituted Analogue
Author(s) -
HoffmannRöder Anja,
Kaiser Anton,
Wagner Sarah,
Gaidzik Nikola,
Kowalczyk Danuta,
Westerlind Ulrika,
Gerlitzki Bastian,
Schmitt Edgar,
Kunz Horst
Publication year - 2010
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201003810
Subject(s) - toxoid , muc1 , tetanus , glycopeptide , antigen , immune system , immunology , immunization , diphtheria toxin , antibody , medicine , vaccination , biology , microbiology and biotechnology , toxin , antibiotics
A “shot in the arm” for cancer therapy : Coupling of synthetic glycopeptide tandem‐repeat sequences of the epithelial mucin MUC1 with the Thomsen–Friedenreich (T) antigen ( A ) or a difluoro analogue ( B ) to tetanus toxoid (TTox) affords synthetic vaccines, which induce very strong immune responses in mice overriding the natural tolerance of the immune system. The induced antibodies are selectively directed against the tumor‐associated MUC1 structures and strongly bind to breast cancer cells of the MCF‐7 cell line.